Nasus Pharma Stock Hits 52-Week Low – Here’s Why

Nasus Pharma Ltd. (AMEX:NSRX) shares are tumbling on Monday. The company announced topline results from its Phase 2 study of NS002, an investigational intranasal epinephrine powder formulation for the treatment of anaphylaxis (severe allergic reaction), during the...